Bolt Biotherapeutics annual return on equity
2021
2022
2023
2024
2025
Bolt Biotherapeutics Return on Equity (ROE) Growth & History (BOLT)
Bolt Biotherapeutics's return on equity was −79.75% for fiscal 2025.
View full Bolt Biotherapeutics company overviewBolt Biotherapeutics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −79.75% | −5.47 pp |
| 2024 | 2024-12-31 | −74.28% | −25.60 pp |
| 2023 | 2023-12-31 | −48.69% | −6.90 pp |
| 2022 | 2022-12-31 | −41.79% | +94.04 pp |
| 2021 | 2021-12-31 | −135.83% | — |
Bolt Biotherapeutics quarterly return on equity
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −47.56% | −27.57 pp |
| Q1 2026 | 2026-03-31 | −31.27% | −10.04 pp |
| Q4 2025 | 2025-12-31 | −22.63% | +2.03 pp |
| Q3 2025 | 2025-09-30 | −20.14% | −0.92 pp |
| Q2 2025 | 2025-06-30 | −19.99% | +2.32 pp |
| Q1 2025 | 2025-03-31 | −21.23% | −11.26 pp |
| Q4 2024 | 2024-12-31 | −24.66% | −9.81 pp |
| Q3 2024 | 2024-09-30 | −19.22% | −7.20 pp |
| Q2 2024 | 2024-06-30 | −22.31% | −10.26 pp |
| Q1 2024 | 2024-03-31 | −9.97% | +0.35 pp |
| Q4 2023 | 2023-12-31 | −14.86% | −3.75 pp |
| Q3 2023 | 2023-09-30 | −12.02% | −1.05 pp |
| Q2 2023 | 2023-06-30 | −12.05% | −1.66 pp |
| Q1 2023 | 2023-03-31 | −10.32% | −0.42 pp |
| Q4 2022 | 2022-12-31 | −11.11% | −0.77 pp |
| Q3 2022 | 2022-09-30 | −10.98% | −2.78 pp |
| Q2 2022 | 2022-06-30 | −10.39% | −2.51 pp |
| Q1 2022 | 2022-03-31 | −9.90% | +14.77 pp |
| Q4 2021 | 2021-12-31 | −10.34% | — |
| Q3 2021 | 2021-09-30 | −8.20% | — |
| Q2 2021 | 2021-06-30 | −7.87% | — |
| Q1 2021 | 2021-03-31 | −24.66% | — |
Bolt Biotherapeutics return on equity trends
Between the periods ended 2021-12-31 and 2025-12-31, Bolt Biotherapeutics's return on equity increased from −135.83% to −79.75%, a change of +56.08 percentage points. The latest reported quarter, Q2 2026, shows −47.56%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Bolt Biotherapeutics source filings ↗